[40] van der Voort van Zijp J, Hoekstra HJ, Basson MD. Evolving management of colorectal cancer. World J
Gastroenterol, 2008, 14: 3956-3967.
[41] Cervantes A, Roselló S, Rodríguez-Braun E, et al. Progress in the multidisciplinary treatment of
gastrointestinal cancer and the impact on clinical practice: perioperative management of rectal cancer. Ann Oncol. 2008 ;19 Suppl 7: vii266-72.
[42] Klautke G, Fietkau R. Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a
review. Int J Colorectal Dis.2007;22: 457-465
[43] Martijnse IS, Dudink RL, Kusters M, et al. T3+ and T4 rectal cancer patients
seem to benefit from the addition of oxaliplatin to the neoadjuvant chemoradiation regimen. Ann Surg Oncol, 2012, 19: 392-401.
[44] Huang K, Haas-Kogan D, Weinberg V, et al. Higher radiation dose with a shorter
treatment duration improves outcome for locally advanced carcinoma of anal canal. World J Gastroenterol, 2007, 13: 895-900.
[45] Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus
radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev, 2009, (1): CD006041.
[46] Soumarova R, Skrovina M, Bartos J, et al. Neoadjuvant chemoradiotherapy with capecitabine followed by
laparoscopic resection in locally advanced tumors of middle and low rectum – toxicity and complications of the treatment. Eur J Surg Oncol, 2010, 36: 251-256.
[47] Roohipour R, Patil S, Goodman KA, et al. Squamous-cell carcinoma of the anal canal: predictors of treatmant
outcome. Dis Colon Rectum, 2008, 51: 147-153.
[48] Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative
chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a muticentre, randomised trial. Lancet, 2009, 373: 811-820.
[49] Siegel R, Burock S, Wernecke KD, et al. Preoperative short-course radiotherapy versus combined
radiochemotherapy in locally advanced rectal cancer: a multi-centre prospectively randomised study of the Berlin Cancer Society. BMC Cancer, 2009, 9: 50.
[50] Vermaas M, Gosselink MP, Ferenschild FT, et al. Introduction of preoperative
radiotherapy in the treatment of operable rectal cancer in the Southwest region of the Netherlands. Eur J Surg Oncol, 2007, 33: 862-867.
[51] Xu J, Zhong Y, Weixin N, et al. Preoperative hepatic and regional arterial chemotherapy in the prevention of
liver metastasis after colorectal cancer surgery. Ann Surg, 2007, 245: 583-590.
[52] de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5-FU/LV in adjuvant colon
cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. J Clin Oncol, 2007, 25(suppl 18): 165s.
[53] Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology, 2008 , 134: 1296-1310.
[54] Samantas E, Dervenis C, Rigatos SK. Adjuvant chemotherapy for colon cancer: evidence on improvement in survival. Dig Dis, 2007, 25: 67-75.
[55] Sargent D, Sobrero A, Grothey A, et al. Evidence for cure by adjuvant therapy in colon cancer: obeservations
based on indiviual patient data from 20, 898 patients on 18 randomized trials. J Clin Oncol, 2009, 27: 872-877.
[56] André L, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovourin
as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol, 2009, 27: 3109-3116. [57] Rodríguez-Moranta F, Saló J, Arcusa A, et al. Postoperative surveillance in patients with colorectal cancer
who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol，2006, 24: 386-393.
[58] Goldberg RM. Therapy for metastatic colorectal cancer. Oncologist, 2006, 11: 981-987.
[59] Tveit KM, Wiig JN, Olsen DR, et al. Combined modality treatment including intraoperative radiotherapy in
locally advanced and recurrent rectal cancer. Radiother Oncol, 1997, 44: 277-282.
[60] Yu TK, Bhosale PR, Crane CH, et al. Patterns of locaregional recurrence after surgery and radiotherapy or
chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys, 2008, 71: 1175-1180.
[61] Fennell ML, Das IP, Clauser S, et al. The organization of multidisciplinary care teams: modeling internal and
external influences on cancer care quality. J Natl Cancer Inst Monogr, 2010, 2010: 72-80.
[62] Rabinowitz B. Interdisciplinary breast cancer care: declaring and improving the standard. Oncology (Williston
Park), 2004, 18: 1263-1270, 1275.
[63] Nordlinger B, Vauthey JN, Poston G, et al. The timing of chemotherapy and surgery for the treatment of
colorectal liver metastases.Clin Colorectal Cancer, 2010, 9: 212-218.
[64] Jones RP, Vauthey JN, Adam R, et al. Effect of specialist decision-making on treatment strategies for
colorectal liver metastases. Br J Surg, 2012, 99: 1263-1269.
[65] Wright FC, De Vito C, Langer B, et al. Multidisciplinary cancer conferences: a systematic review and
development of practice standards. Eur J Cancer, 2007, 43: 1002-1010.
[66] Davies AR, Deans DA, Penman I, et al. The multidisciplinary team meeting improves staging accuracy and
treatment selection for gastro-esophageal cancer. Dis Esophagus, 2006, 19: 496-503.
[67] Fleissig A, Jenkins V, Catt S, et al. Multidisciplinary teams in cancer care: are they effective in the
UK? Lancet Oncol, 2006, 7: 935-943.
[68] Gabel M, Hilton NE, Nathanson SD. Multidisciplinary breast cancer clinics. Do they work? Cancer, 1997, 79:
2380-2384.
[69] Abdalla EK. Resection of colorectal liver metastases. J Gastrointest Surg, 2011, 15: 416-419.
[70] Carter S, Garside P, Black A. Multidisciplinary team working, clinical networks, and chambers; opportunities
to work differently in the NHS. Qual Saf Health Care, 2003, 12 Suppl 1: i25-i28.
[71] Rummans TA, Clark MM, Sloan JA, et al. Impacting quality of life for patients with advanced cancer with a
structured multidisciplinary intervention: a randomized controlled trial. J Clin Oncol, 2006, 24: 635-642. [72] Westin T, Stalfors J. Tumour boards/multidisciplinary head and neck cancer meetings: are they of value to
patients, treating staff or a political additional drain on healthcare resources? Curr Opin Otolaryngol Head Neck Surg, 2008, 16: 103-107.
[73] Stephens MR, Lewis WG, Brewster AE, et al. Multidisciplinary team management is associated with
improved outcomes after surgery for esophageal cancer. Dis Esophagus, 2006, 19: 164-171.
[74] Du CZ, Li J, Cai Y, et al. Effect of multidisciplinary team treatment on outcomes of patients with
gastrointestinal malignancy. World J Gastroenterol, 2011, 17: 2013-2018.
[75] MacDermid E, Hooton G, MacDonald M, et al. Improving patient survival with the colorectal cancer
multi-disciplinary team. Colorectal Dis, 2009, 11: 291-295.
[76] Obias VJ, Reynolds HL Jr. Multidisciplinary teams in the management of rectal cancer. Clin Colon Rectal
Surg, 2007, 20: 143-147.
[77] Look Hong NJ, Gagliardi AR, Bronskill SE, et al. Multidisciplinary cancer conferences: exploring obstacles
and facilitators to their implementation. J Oncol Pract, 2010, 6: 61-68.
[78] Bentrem DJ, DeMatteo RP, Blumgart LH. Surgical therapy for metastatic disease to the liver. Ann Rev Med.
2005;56: 139-156.
[79] Abdalla EK. Commentary: Radiofrequency ablation for colorectal liver metastases : do not blame the biology
when it is the technology.Am J Surg, 2009, 197: 737-739.
[80] Hur H, Ko YT, Min BS, et al. Comparative study of reseaction and radiofrequency ablation in the treatment of
solitary colorectal liver metastases. Am J Surg, 2009, 197: 728-736.
[81] Reuter NP, Woodall CE, Scoggins CR, et al. Radiofrequency ablation vs. resection for hepatic colorectal
metastasis: therapeutically equivaient? J Gastrointest Surg, 2009, 13: 486-491.
[82] Dexiang Z, Li R, Ye W, et al. Outcome of patients with colorectal liver metastasis: analysis of 1, 613
consecutive cases. Ann Surg Oncol, 2012, 19: 2860-2868.
[83] Lochan R, White SA, Manas DM. Liver resection for colorectal liver metastasis. Surg Oncol, 2007, 16: 33-45. [84] Adam R. Current surgical strategies for the treatment of colorectal cancer liver metastases. Eur J Cancer
Supplements, 2004, 2: 21-26.
[85] Pawlik TM, Scoggins CR, Zorzi D, et al. Effect of surgical margin status on survival and site of recurrence
after hepatic resection for colorectal metastases. Ann Surg, 2005; 241: 715-722.
[86] Yan TD, Padang R, Xia H, et al. Management of involved or close resection margins in 120 patients with
colorectal liver metastases: edge cryotherapy can achieve longterm survival. Am J Surg 2006;191: 735-42. [87] Blatzer DG 3rd, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome
end poin after resection of hepatic colorectal metastases. J Clin Oncol 2008, 26: 5344-5341.
[88] Alberts SR, Wagman LD. Chemotherapy for colorectal cancer liver metastases. Oncologist. 2008;13:
1063-1073.
[89] Jaeck D. The significance of hepatic pedicle lymph nodes metastases in surgical management of colorectal
liver metastases and of other liver malignancies. Ann Surg Oncol. 2003;10: 1007-1011.
[90] Pulitanò C, Bodingbauer M, Aldrighetti L, et al. Colorectal liver metastasis in the setting of lymph node
metastasis: defining the benefit of surgical resection. Ann Surg Oncol, 2012, 19: 435-442.
[91] Jaeck D, Oussoultzoglou E, Rosso E. Hepatectomy for colorectal metastases in the presence of extrahepatic
disease. Surg Oncol Clin N Am 2007;16: 507-523.
[92] Miller G, Biernacki P, Kemeny NE, et al. Outcomes after resection of synchronous or metachronous hepatic
and pulmonary metastases. J Am Coll Surg 2007;205: 231-238.
[93] Pulitanò C, Bodingbauer M, Aldrighetti L, et al. Liver resection for colorectal metastases in presence of
extrahepatic disease: results from an international multi-institutional analysis. Ann Surg Oncol, 2011, 18: 1380-1388.
[94] Chua TC, Saxena A, Liauw W, et al. Hepatectomy and resection of concomitant extrahepatic disease for
colorectal liver metastases--a systematic review. Eur J Cancer, 2012, 48: 1757-1765.
[95] Gonzalez M, Ris HB, Krueger T, et al. Colorectal cancer and thoracic surgeons: close encounters of the third
kind. Expert Rev Anticancer Ther, 2012, 12: 495-503.
[96] Hao CY, Ji JF. Surgical treatment of liver metastases of colorectal cancer: Strategies and controversies in 2006. Eur J Surg Oncol, 2006, 32: 473-483.
[97] Turrini O, Viret F, Guiramand J, et al. Strategies for the treatment of synchronous liver metastasis. Eur J Surg
Oncol, 2007, 33: 735-740.
[98] Otchy D, Hyman NH, Simmang C, et al. Practice parameters for colon cancer. Dis Colon Rectum, 2004, 47:
1269-1284.
[99] Capussotti L, Ferrero A, Viganò L, et al. Major liver resection synchronous with colorectal surgery. Ann Surg
Oncol , 2007, 14: 195-201.
[100] Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the
liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer, 1996, 77: 1254-1262.
[101] Nakajima K, Takahashi S, Saito N, et al. Predictive factors for anastomotic leakage after simultaneous
resection of synchronous colorectal liver metastasis. J Gastrointest Surg, 2012, 16: 821-827.
[102] Schnitzbauer AA, Lang SA, Goessmann H, et al. Right portal vein ligation combined with in situ splitting
induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg, 2012, 255: 405-414.
[103] Roxburgh CS, Richards CH, Moug SJ, et al. Determinants of short- and long-term outcome in patients
undergoing simultaneous resection of colorectal cancer and synchronous colorectal liver metastases. Int J Colorectal Dis, 2012, 27: 363-369.
[104] Slupski M, Wlodarczyk Z, Jasinski M, et al. Outcomes of simultaneous and delayed resections of
synchronous colorectal liver metastases. Can J Surg, 2009, 52: E241-E244.
[105] Weber JC, Bachellier P, Oussoultzoglow E, et al. Simultaneous resection of colorectal primary tumour and
synchronous liver metastases. Br J Surg, 2003, 90: 956-962.
[106] Moug SJ, Horgan PG. The role of synchronous procedures in the treatment of colorectal liver metastases.
Surg Oncol, 2007, 16: 53-58.
[107] de Jong MC, van Dam RM, Maas M, et al. The liver-first approach for synchronous colorectal liver
metastasis: a 5-year single-centre experience. HPB (Oxford), 2011, 13: 745-752.
[108] Aloia TA, Fahy BN. A decision analysis model predicts the optimal treatment pathway for patients with
colorectal cancer and resectable synchronous liver metastases. Clin Colorectal Cancer, 2008, 7: 197-201. [109] Mentha G, Majno PE, Andres A, et al. Neoadjuvant chemotherapy and resection of advanced synchronous
liver metastases before treatment of the colorectal primary. Br J Surg, 2006, 93: 872-878. [110] Brouquet A, Mortenson MM, Vauthey JN, et al. Surgical strategies for synchronous colorectal liver
metastases in 156 consecutive patients: classic, combined or reverse strategy? J Am Coll Surg, 2010, 210: 934-941.
[111] Mentha G, Roth AD, Terraz S, et al. \
synchronous liver metastases. Dig Surg, 2008, 25: 430-435.
[112] Van Dessel E, Fierens K, Pattyn P, et al. Defining the optimal therapy sequence in synchronous resectable
liver metastases from colorectal cancer: a decision analysis approach. Acta Chir Belg, 2009, 109: 317-320. [113] van der Pool AE, de Wilt JH, Lalmahomed ZS, et al. Optimizing the outcome of surgery in patients with
rectal cancer and synchronous liver metastases. Br J Surg, 2010, 97: 383-390.
[114] Tomlinson JS, Jarnagin WR, DeMatteo RP, et al. Actual 10-year survival after resection of colorectal liver
metastases defines cure. J Clin Oncol, 2007, 25: 4575-4580.
[115] Pelosi E, Deandreis D. The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in
the management of patients with colorectal cancer. Eur J Surg Oncol, 2007, 33: 1-6.
[116] Shoup M, Gonen M, D′Angelica M, et al. Volumetric analysis predicts hepatic dysfunction in patients
undergoing major liver resection. J Gastrointest Surg, 2003, 7: 325-330.
[117] Sarpel U, Bonavia AS, Grucela A, et al. Does anatomic versus nonanatomic resection affect recurrence and
survival in patients undergoing surgery for colorectal liver metastasis? Ann Surg Oncol, 2009, 16: 379-384. [118] Clavien PA, Petrowsky H, DeOliveira ML, et al. Strategies for safer liver surgery and partial liver
transplantation. N Engl J Med, 2007, 356: 1545-1559.
[119] Ayez N, Lalmahomed ZS, Eggermont AM, et al. Outcome of microscopic incomplete resection (R1) of
colorectal liver metastases in the era of neoadjuvant chemotherapy. Ann Surg Oncol, 2012, 19: 1618-1627. [120] Yamamoto J, Shimada K, Kosuge T, et al. Factors infuencing survival of patients undergoing hepatectomy
for colorectal metastases. Br J Surg, 1999, 86: 332-337.
[121] Kokudo N, Miki Y, Sugai S, et al. Genetic and histological assessment of surgical margins in resected liver
metastases from colorectal carcinoma: minimum surgical margins for successful resection. Arch Surg, 2002, 137: 833-840.
[122] Neeleman N, Andersson R. Repeated liver resection for recurrent liver cancer. Br J surg, 1996, 83: 893-901. [123] Antoniou A, Lovegrove RE, Tilney HS, et al. Meta-analysis of clinical outcome after first and second liver
resection for colorectal metastases. Surgery 2007;141: 9-18.
[124] Adam R, Hoti E, Bredt LC. Evolution of neoadjuvant therapy for extended hepatic metastases-have we
reached our (non-resectable) limit? J Surg Oncol, 2010, 102: 922-931.
[125] Warwick R, Page R. Resection of pulmonary metastases from colorectal carcinoma. Eur J Surg Oncol, 2007, 33(suppl 2): S59-S63.
[126] Elias D, Benizri E, Pocard M, et al. Treatment of synchronous peritoneal carcinomatosis and liver metastases from colorectal cancer. Eur J Surg Oncol, 2006, 32: 632-636.
[127] Carpizo DR, D\
disease. Ann Surg Oncol, 2009, 16: 2411-2421.
[128] Ciliberto D, Prati U, Roveda L, et al. Role of systemic chemotherapy in the management of resected or
resectable colorectal liver metastases: a systematic review and meta-analysis of randomized controlled trials. Oncol Rep, 2012, 27: 1849-1856.
[129] Ismaili N. Treatment of colorectal liver metastases. World J Surg Oncol, 2011, 9: 154.
[130] Cleary JM, Tanabe KT, Lauwers GY, et al. Hepatic toxicities associated with the use of preoperative
systemic therapy in patients with metastatic colorectal adenocarcinoma to the liver. Oncologist, 2009, 14: 1095-1105.
[131] Nordlinger B, Sorbye H, Collette L, et al. Final results of the EORTC Intergroup randomized phase III study
40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol, 2007, 25(Suppl 18): LBA5.
[132] Tanaka K, Adam R, Shimada H, et al. Role of neoadjuvant chemotherapy in the treatment of multiple
colorectal metastases to the liver. Br J Surg, 2003, 90: 963-969.